Caisse Des Depots ET Consignations Purchases Shares of 1,540 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Caisse Des Depots ET Consignations acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 1,540 shares of the company’s stock, valued at approximately $637,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of IDXX. FSA Wealth Management LLC purchased a new position in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories during the 4th quarter valued at $31,000. Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories during the 4th quarter valued at $38,000. Finally, Crews Bank & Trust bought a new stake in IDEXX Laboratories in the 4th quarter worth $41,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on IDXX shares. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Barclays increased their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday. Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Finally, Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Up 1.2 %

Shares of NASDAQ IDXX opened at $422.54 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a 50-day moving average of $437.13 and a 200 day moving average of $443.72. The stock has a market cap of $34.25 billion, a P/E ratio of 39.60, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.